Spanish Study Confirms Safety and Efficacy of Mixing COVID-19 Vaccines
Research indicates significant immune response from Pfizer vaccine following AstraZeneca dose.
A study conducted in Spain has found that administering a dose of the Pfizer-BioNTech COVID-19 vaccine to individuals who have already received a single dose of the AstraZeneca vaccine is both safe and effective.
The research, conducted by the Carlos III Health Institute, a state-supported public health organization, revealed that the immune response in individuals who received the Pfizer dose increased by a factor of 30 to 40 compared to those who only received the AstraZeneca vaccine.
The study involved 600 participants.
Researchers noted that only a small number of serious side effects were observed among the study participants, indicating a promising safety profile for the mixed vaccination strategy.
This finding adds to the growing body of evidence regarding the effectiveness of heterologous vaccination regimens in enhancing immunity against COVID-19.
The research, conducted by the Carlos III Health Institute, a state-supported public health organization, revealed that the immune response in individuals who received the Pfizer dose increased by a factor of 30 to 40 compared to those who only received the AstraZeneca vaccine.
The study involved 600 participants.
Researchers noted that only a small number of serious side effects were observed among the study participants, indicating a promising safety profile for the mixed vaccination strategy.
This finding adds to the growing body of evidence regarding the effectiveness of heterologous vaccination regimens in enhancing immunity against COVID-19.
